logo-loader
viewBoston Scientific

Boston Scientific rises as preliminary 4Q sales figures match consensus estimate

For all of 2018, the company reported an 8.6% gain in preliminary sales to $9.82 billion

A surgeon putting on gloves
For all of 2018, Boston Scientific reported a 8.6% gain in preliminary sales

Boston Scientific Corp (NYSE:BSX) advanced Tuesday after reporting preliminary fourth-quarter sales figures that were in line with the consensus estimate.

The Marlborough, Massachusetts-based medical products company said preliminary sales increased 6.3% on a reported based during the fourth quarter to $2.56 billion. That matched the average estimate of analysts.

READ: Johnson & Johnson third-quarter results beat estimates; raises guidance for 2018

Shares of Boston Scientific rose $0.47, or 1.4%, to $34.89 in New York Stock Exchange trading.
 
For all of 2018, the company reported an 8.6% gain in preliminary sales to $9.82 billion.

Highlights included a 10.9% gain in its urology and pelvic health segment and 6.4% growth in its cardiovascular business.

Contact Dennis Fitzgerald at [email protected]

Quick facts: Boston Scientific

Price: 34.64 USD

NYSE:BSX
Market: NYSE
Market Cap: $49.49 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tabula launches new ETF focussing on North American High Yield Credit Market

Tabula Investment Management Limited (LSE: TABS) CEO MJ Lytle joined Steve Darling from Proactive with news the company has started a new ETF that will be exclusively located on the London Stock Exchange under the ticker “TABS”  Lytle telling Proactive that ETF will focus on short exposure...

17 hours, 44 minutes ago

2 min read